SCHEMBL1374441

SCHEMBL1374441

Nc1cc(O)ccc1CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 3/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
TYR P14679 6/20 0.44
ALOX5 P09917 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 2/20 0.36
ALOX15 P16050 2/20 0.36
CA3 P07451 1/20 0.36
THRB P10828 1/20 0.36
CA6 P23280 1/20 0.36
CASP1 P29466 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
USP7 Q93009 1/20 0.34
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152516 0.82 TYR (0.46) CA14CA12CA1CA2CA7
SCHEMBL30680234 0.81 CA14 (0.48) CA14CA12CA1CA2CA7
SCHEMBL33650 0.81 CA14 (0.43) CA14CA12CA1CA2CA7
SCHEMBL11848169 0.81 CA14 (0.48) CA14CA12CA1CA2CA7
SCHEMBL1425128 0.81 CA12 (0.48) CA14CA12CA1CA2CA7
SCHEMBL28279531 0.79 CA14 (0.41) CA14CA12CA1CA2CA7
SCHEMBL31621881 0.79 CA14 (0.46) CA14CA12CA1CA2CA7
SCHEMBL10388709 0.79 CA14 (0.52) CA14CA12CA1CA2CA7
SCHEMBL2314917 0.79 TYR (0.44) CA14CA12CA1CA2CA7
SCHEMBL692702 0.78 CASP1 (0.42) CA1CA2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2592083-A1 FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2013-05-15 EP disclosed
US-20110288086-A1 POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2011-11-24 US disclosed
EP-0331144-B1 3-SUBSTITUTED PARA-AMINO PHENOLS, PROCESS FOR THEIR PREPARATION, THEIR USE IN DYEING KERATENIC FIBRES AND INTERMEDIATES USED IN THE PREPARATION PROCESS L'OREAL (FR) 1993-06-09 EP disclosed
EP-0331144-A2 3-Substituted para-amino phenols, process for their preparation, their use in dyeing keratenic fibres and intermediates used in the preparation process L'OREAL (FR) 1989-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288086-A1 POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF AURKA, AURKC, AURKB CA14 2303/4885CA12 3331/4885CA1 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.